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Abstract  
Introduction: Thrombolysis has radically changed the prognosis of acute ischemic stroke. Tenecteplase is a modified form of rt-PA with greater 
specificity for fibrin and a longer half-life. We report the experience of a Moroccan tertiary hospital in thrombolysis using Tenecteplase. 
Methods: We conducted an open prospective study of all patients who were treated with Tenecteplase for an acute ischemic stroke admitted to 
our emergency department. Tenecteplase was administered intravenously at a dose of 0.4 mg/kg single bolus. The primary outcome measure was 
the proportion of patients achieving significant early neurological recovery defined as an improvement of 4 or more points on the NIHSS score at 
24h. Results: 13 patients had been treated by intravenous thrombolysis. 31% were women. Mean age was 63 years old. The mean NIHSS score 
at admission was 14.3 and 24h after was at 9.1. The right middle cerebral artery was involved in 69% of cases. The carotid atherosclerosis was 
predominant 63.3% and the cardio embolic etiology 27%. The mean time to the first medical contact after the onset of symptoms was 3h 30 min. 
One patient presented a capsulo-lenticular hematoma of 5 mm3 in the same side of the ischemic stroke. Conclusion: Tenecteplase is a more 
interesting thrombolytic than alteplase, it seems to be more suitable for thrombolysis in our center. 
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Introduction 
 
The intravenous thrombolysis with rt-PA has radically changed the 
prognosis of stroke [1-3]. Scholarly societies recommend the 
admission of these patients and the realization of thrombolysis in 
stroke units [4,5]. The establishment of such units in developing 
countries, such as Morocco, encounters difficultiesand these units 
are slow to start. Other barriers are encountered, as short 
therapeutic window, the lack of information of the population that 
continues to ignore the main clinical signs and the absence of pre-
hospital care standardized. This shows the complexity of this 
problem in our country. Classically, Alteplase is used to perform this 
type of thrombolysis; however, some studies have shown the 
superiority of Tenecteplase [6-8], its ease of handling and the time 
of its action to better take advantage of the short window therapy. 
Our choice was instinctively focused on thrombolysis by 
Tenecteplase that seemed more suited to our context. We report 
our experience in thrombolysis for acute ischemic stroke in 13 
patients all treated with Tenecteplase (Metalyse®), they were all 
registred at the emergency department of the Mohammed V Military 
Hospital of instruction, which is a tertiary hospital in Rabat. Our 
emergency department has within it an emergency intensive care 






We conducted an open prospective study of all patients who were 
treated with Tenecteplase for anacute ischemic stroke admitted to 
the emergency department of the Military Hospital Mohammed V. 
the whole departments taff received a training about thrombolysis 
with awareness to the importance of time factor "time is brain". 
Physicians have been also trained to the assessment of neurological 
status by calculating the NIHSS score. This score counts 15 items 
that measure the depth of the neurological deficit quoted from 0 to 
42, <5 it reflects a minor deficit and > 25 severe neurological 
impairment. In consultation with the medical imaging department, 
access to MRI was facilitated during the day and to the CT scan 
during the night. The presence of a neurologist was requested 
without delaying patients care. All patients who were admitted to 
our department in the period between June 2010 and October 2014, 
with symptoms suggestive of Stroke 4h30min after onset were 
immediately assessed by a senior emergency physician to decide on 
their Eligibility for intravenous thrombolysis. We first conducted a 
quick but detailed clinical examination with capillary blood glucose 
monitoring, record of personal and family medical history, 
calculation of NIHSS score. At the same time we did standard 
laboratory tests, ECG and chest X-ray. We have respected the same 
inclusion and exclusion criteria as those adopted in the ECASS 3 
study [3] (Table 1). The family consent, after discussion of the 
benefit and complications of this treatment was obtained for each 
patient who could not give it himself. Tenecteplase was 
administered intravenously at a dose of 0.4 mg/kg single bolus. 
Patients who received thrombolytic therapy were the subject of a 
prospective study. The collected variables were the time of onset of 
symptoms, the time of arrival to the emergency room, demographic 
data, risk factors for ischemic stroke, a detailed neurological 
examination with calculation of the NIHSS score (which was done 
on admission, 1h, 2h, and 24h after administration of 
Tenecteplase), monitoring of systolic and diastolic blood pressure 
and blood glucose on admission, time of completion of the imaging 
and its results, Tenecteplase administration time. Types of stroke 
were defined by the Criteria used in TOAST study [9]. The primary 
outcome measure was the proportion of patients achieving 
significant early neurological recovery defined as an improvement of 
4 or more points on the NIHSS score at 24h. The safety endpoint 
was the rate of symptomatic intracranial hemorrhage (SICH) and 
death. SICH was defined according to the NINDS rt-PA/Cochrane 
criteria as any new evidence of intracranial blood on CT or magnetic 
resonance imaging (MRI) accompanied by a neurological 





From June 2010 to October 2014, 13 patients had undergone 
intravenous thrombolysis using Tenecteplase at maximum of 
4h30min after the onset of a neurological impairment following an 
acute ischemic stroke in the carotid territory. 31% were women 
(4/13). The mean age was 63 years (± 15). Most of them arrived to 
the hospital using their own vehicle (10/13 or 77%), or after a call 
to the emergency department from the family doctor followed by a 
non-medical transport to hospital (23%). The mean NIHSS score at 
admission was 14.3 (±7), 2 hours after thrombolysis it was 12.8 
(±8) and 24h after was at 9.1 (± 9). We also noted that 77% of our 
patients have improved their score NHISS more than 4 points. Prior 
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to injection of thrombolytic, brain CT scan without contrast was 
performed in 5 patients (38%) showing early signs of ischemia 
(dedifferentiation cortico-subcortical, deletion of the insular ribbon, 
deletion of the lenticular nucleus, spontaneous and asymmetric 
hyper density of the middle cerebral artery). Brain MRI diffusion / 
perfusion was performed for the remaining patients (8/13 or 62%). 
We respected the deadline for the treatment of 4h30min after the 
onset of symptoms for all our patients. Strokes in the territory of the 
right middle cerebral artery represented 69% (9/13) of cases. The 
carotid atherosclerosis was predominant (63.3%) and the 
cardioembolic etiology (27%). Undetermined causes accounted for 
the rest of cases (9.7%) (Table 2). The mean time to the first 
medical contact after the onset of symptoms was 3h 30 min 
(±35min). The average "door to treatment" time, or the time 
between hospital admission and the beginning of the injection of 
fibrinolytic treatment was 40 minutes (±20min). Only one patient 
presented a capsulo lenticular hematoma of 5 mm3 in the same side 
of the ischemic stroke. He presented an uncontrolled high blood 
pressure 220/130 mmHg, half an hour after administration of 
thrombolytic therapy. Control CT scans, showed that the hematoma 
had kept the same volume without requiring surgery. No deaths 





All over the world, one person every 5 seconds undergoes a stroke. 
Labbé O. & Massart J. (2010) [10]. Moreover, in France, the annual 
incidence of stroke is 1.6 to 2.4 per 1000 people, representing from 
100000 to 145000 strokes per year, 15 to 20% of them will die after 
the first month and 75% them will survive with sequelae. In 
Morocco, the results of the survey of stroke, conducted among 
13,000 households between November 2008 and May 2009, in the 
region of Rabat-Salé-Zemmour-Zaer and Grand Casablanca, 
revealed 90,000 cases of which 50,000 came from the rural against 
40,000 from the urban areas. The working group ECASS3 had set a 
target to treat patients within four and a half hours after the onset 
of symptoms, with an intra-hospital delay "door to treatment" of up 
to 1 hour. In our series all patients were treated respecting this 
delay of 4h30min after symptom onset. This reinforces the need to 
educate health professionals and the general public about the stroke 
symptoms, so that these patients can be quickly identified and 
treated. The promotion of pre-hospital medicine is the key to 
improving these deadlines. In our series the intra hospital 
management delay was less than one hour (mean time: 40 
minutes), thanks to the involvement of all stakeholders. In the other 
series, this time ranges from 96 minutes [10] to 33 min [11]. It 
should be reduced by convening more meetings of the various 
stakeholders and raising awareness of the fact that faster is the 
treatment better are the results. Tenecteplase is a modified form of 
rt-PA with greater specificity for fibrin and a longer half-life. Our 
study confirms the benefits seen in other studies comparing 
Tenecteplase with Alteplase and have shown that the clinical benefit 
is not burdened with increased bleeding [6-8]. Indeed, at a dose of 
0.4 mg/kg we have encountered a single bleeding episode which 
was due to an uncontrolledhigh blood pressure and has not 
worsened after blood pressure control. After thrombolysis 
significantly reduction of the NIHSS score was observed in 77% of 
our patients. NHISS average score on admission was 14.3 and it has 
fallen to 9.1 after 24 hours. Major neurological improvement, 
defined by Saposnik & al [12] by a NHISS score of 0 points or an 
improvement of more than 8 points, was noted in 7 of our patients 
(54%) (Table 3) [1,13-15]. Our results are probably due to the 
rigorous selection of patients eligible for thrombolysis and respect 





The protocol of thrombolysis, used in our center to date, seems 
convincing. Tenecteplase is a more interesting thrombolytic than 
Alteplase, which has proven itself in the thrombolysis in myocardial 
infarction. It seems to be more suitable for thrombolysis in centers 
that are not equipped with stroke units as well as for countries 
where pre-hospital medicine is in its beginnings. The short time of 
its action allows to better taking advantage of the short window 
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Table 1: Exclusion and inclusion criteria according to the NINDS and ECASS 3 studies and which 
were adopted in our study 
Main inclusion criteria Main exclusion criteria 
Acute ischemic stroke Intracrânial haemorrhage 
Age, 18 to 80 years Time of symptom onset unknown 
Onset of stroke symptoms 3 
to 4.5 hours before initiation 
of study-drug administration 
Symptoms rapidly improving or only minor before start of infusion 
Stroke symptoms present for 
at least 30 minutes with no 
significant improvement 
before treatment 
Severe stroke as assessed clinically (e.g., NIHSS score >25) or by 
appropriate imaging techniques* 
  Seizure at the onset of stroke 
  Stroke or serious head trauma within the previous 3 months 
  Combination of previous stroke and diabetes mellitus 
  Administration of heparin within the 48 hours preceding the onset of 
stroke, with an activated partial-thromboplastin 
  Time at presentation exceeding the upper limit of the normal range 
  Platelet count of less than 100,000 per cubic millimetre 
  Systolic pressure greater than 185 mmHg or diastolic pressure 
greater than 110 mmHg, or aggressive treatment (intravenous 
medication) necessary to reduce blood pressure to these limits 
  Blood glucose less than 50 mg per decilitre or greater than 400 mg 
per decilitre 
  Symptoms suggestive of subarachnoid haemorrhage, even if 
imagery was normal 
  Oral anticoagulant treatment 
  Major surgery or severe trauma within the previous 3 months 
  Other major disorders associated with an increased risk of bleeding 
* A severe stroke as assessed by imaging was defined as a stroke involving more than one third of 
the middle cerebral artery territory. NIHSS denotes National Institutes of Health Stroke Scale in which 
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Table 2: Baseline characteristics of our 13 patients 









Age (mean ± S.D) 63±15 
 
68±11 
Female (%) 31 
 
42 
Weight (kg) 60±11 
 
76±16 

























   Large vessel occlusive 41.3 
 
37 







Tableau 3: Proportions of patients who have shown an 
improvement of more than 4 points on the NHISS score in several 
studies 




NIHSS score % 
HMIMV 13 77,0 
New delhi (13) 54 66,7 
GSH (14) 42 67,0 
Thailand 2006 (15) 34 70,6 
NINDS rt-PA (1) 312 47,0 
 
 
